2μg (R: reducing condition, N: non-reducing condition).
Product Details
Product Details
Product Specification
Species | Human |
Synonyms | FIL1 epsilon, IL-1 epsilon, IL-1F6, IL-1H1 |
Accession | Q9UHA7 |
Amino Acid Sequence | Lys6-Phe158 |
Expression System | E.coli |
Molecular Weight | 17kDa (Reducing) |
Purity | >95% by SDS-PAGE |
Endotoxin | <0.1EU/μg |
Conjugation | Unconjugated |
Tag | No Tag |
Physical Appearance | Lyophilized Powder |
Storage Buffer | 20mM Tris, 50mM NaCl, pH8.0, 2mM DTT, 5%trehalose |
Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
Reference | O'Reilly S. Interleukin-36α is elevated in diffuse systemic sclerosis and may potentiate fibrosis. Cytokine. 2022 Aug;156:155921. . Epub 2022 Jun 3. |
Background
Interleukin-36 (IL-36) is part of the larger IL-1 family of cytokines and includes three agonists, IL-36α, IL-36β and IL-36γ, and two inhibitors, IL-36RA and IL-38. IL-36α is proteolytically cleaved to its active form, primarily by neutrophil proteases, yielding an active cytokine. IL-36Ra is the antagonist that is specific for IL-36α, β, γ and does this by binding to ILRrp2, in an analogous way to IL-1Ra inhibition of IL-1β. IL-36 signalling activates mitogen-activated protein kinases (MAPKs) and NF-KB resulting in downstream target gene activation. IL-36 signals through the IL-36 Receptor and its co-receptor IL1R accessory protein is necessary for downstream signalling. IL-36α functions primarily in skin and demonstrates increased expression in psoriasis. In addition, decreased expression of this protein has been linked to a poor prognosis in both hepatocellular carcinoma and colorectal cancer patients.
Picture
Picture
SDS-PAGE
